European oncology congress: therapeutic advances against cancer

Late October 2026, several announcements report therapeutic advances against cancer: an immunotherapy extending survival in small-cell lung cancer, a new family of drugs for gynecological cancers, and a personalized melanoma vaccine showing promising results. On October 27, a study indicates that second-generation hormone therapy as a complement significantly prolongs survival in metastatic prostate cancer. On October 29, Professor Jean-Jacques Kiladjian highlights the gap between announcements of promising treatments and their effective access for patients, after the European oncology congress. Late October, a European oncology summit notably presents the melanoma vaccine and new promising treatments. Early November, studies mention enhanced immunotherapies and antibody-drug conjugates against resistant tumors, ultrasound for prostate cancer, funding for the French ATLAS team on autoantibodies, and therapeutic vaccines as a growing avenue.